Please assess the completion status of the following clinical trial:

Trial Title: Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of B-cell chronic lymphocytic leukemia or lymphoplasmocytic lymphoma (Waldenstrom's macroglobulinemia)~  * Must have poor prognostic features and low probability of successful autografting, defined by one of the following criteria:~    * Progressive disease with unfavorable cytogenetics (deletion or mutation of critical regions on chromosomes 11q and/or 17p \[p53\]; and/or unmutated status of the immunoglobulin V_H gene region; and/or usage of the V_H 3-21 gene), defined as 1 of the following:~      * Doubling of lymphocyte count or nodal involvement within 3 months or less~     * Progressive decline of platelet count and/or hemoglobin values defining Binet stage C disease (or to 50% or less of baseline values within 3 months) not due to immune mechanisms~     * Symptomatic splenomegaly~     * Discomfort or imminent complications due to large tumor masses~     * B symptoms~   * Refractory disease or early relapse (within 12 months) after treatment with a fludarabine-containing regimen~   * Relapsed after autologous stem cell transplant (SCT)~   * Insufficient stem cell harvest for intended autologous SCT~* Presence of a clonal CDR III rearrangement detected by polymerase chain reaction~* No Richter's syndrome~* HLA-identical sibling or unrelated donor available~PATIENT CHARACTERISTICS:~* ECOG performance status ≤ 1~* Creatinine clearance \> 60 mL/min~* SGOT, SGPT, and bilirubin \< 2 times normal~* Normal cardiac function determined by ECG and echocardiographic examination~* Inspiratory vital capacity, FEV_1, and DLCO \> 50% of predicted~* No serious localized or systemic infections~* No other concurrent malignant disease~* No impaired organ function~* No uncontrolled diabetes~* No uncontrolled hypertension~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No HIV infection~* No hepatitis B or C infection~* No concurrent alcohol or drug abuse~* No dementia or altered mental status that would preclude giving informed consent~PRIOR CONCURRENT THERAPY:~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Allogeneic stem cell transplantation (Type: EXPERIMENTAL): 1. Cytoreductive therapy for inducing a state of partial remission:~   FC or FC-R or alternative salvage regimens (e.g. Alemtuzumab)~2. Conditioning regimen:~   FC +/- ATG (Arm A) or FC/Busulfan +/- ATG (Arm C: refractory patients only)~3. allogeneic-PBSCT (from HLA-identical donor)~4. GVHD prophylaxis: CSA + MTX or MMF~5. +/- DLI (Donor lymphocyte infusions)

Based on this trial design, predict the completion outcome and termination type (if applicable).